Innlegg rette etter nærmere studering av patentet.
Patentsøknaden var rett nok filet 9 NOV 2019, men dette er nok ikke relatert til fimaVACC men til noe helt nytt og revolusjonerende. Selv om teknologien er den samme som benyttes ved fimaVACC .
I patentet kan man lese følgende:
« Surprisingly it has now been found that PCI of antibacterial agents provides a simple mechanism for killing intracellular bacteria»
PCI methods provide a mechanism for introducing molecules into the cytosol of a cell in a manner which does not result in widespread cell destruction or cell death if the methodology is suitably adjusted to avoid excessive toxic species production, e.g. by lowering illumination times or photosensitizer dose.»
«This method of the invention is particularly advantageous because it is not a complex method and may be used with a variety of antibacterial agents and different target bacteria. It also allows the use of lower concentrations of the antibacterial agent than is required for conventional methods, whilst achieving effective antibiotic effects. This prevents resistance development. Furthermore, the timing and location of irradiation to release the molecules may be controlled such that it is released only at the time and location that is desired to achieve the required effects. As such, exposure of cells to the various components is minimised, and undesirable side effects are minimised. This is in contrast to the standard techniques for antibacterial treatment, where it is not possible to control the timing and location of the release of the various components and high concentrations of the various components and/or their carriers are needed»
Her er det bare å glede seg. Dette er fantastiske nyheter og sant og si så skjønner jeg ikke hvorfor slike nyheter ikke børsmeldes. For når PCIB nå trolig har en løsning på resistens, så vil der skape jordskjelv i visse kretser! Og hva er ikke inntjeningspotensiale med en slik patent?
Gratulerer med dagen!
